Debbie Dingell actually said...
We have heard some arguments here today that, if H.R. 3 were to become law, then there is a likelihood that innovation would be driven to China. I think that this is a red herring, let's be clear, because absolutely nothing in H.R. 3 is closing the U.S. market for drug manufacturers or drug development.
Context
Dingell argues against claims that H.R. 3 would harm U.S. drug innovation.
05/03/2021